Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOXA1-dependent responses of the HER2+ SKBR-3 cell line to lapatinib

ABSTRACT: SKBR-3 HER2+ breast cancer cells were treated with 25 nM Dharmacon siGENOME non-targeting (NT) siRNA control pool or siRNA pool targeting FOXA1 for 48h, then treated with either DMSO or 300nM lapatinib for 24h.

ORGANISM(S): Homo sapiens

PROVIDER: GSE160001 | GEO | 2020/10/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Adaptive responses of the HER2+ SKBR-3 and BT474m1 cell lines to lapatinib and JQ1

Project description:SKBR-3 or BT474m1 HER2+ breast cancer cells were treated with either DMSO, 300nM lapatinib, 300nM JQ1, or lapatinib and JQ1 in combination for 48h.

2020-10-26 | GSE160018 | GEO

Enhancer analysis of HER2+ cell lines SKBR-3 (ER-) and BT474m1 (ER+) in response to lapatinib and JQ1 and analysis of FOXA1 chromatin binding in SKBR-3 cells in response to lapatinib and JQ1 and impact of FOXA1 knockdown on BRD4 and MED1

Project description:SKBR-3 and BT474m1 HER2+ breast cancer cell lines were treated with lapatinib, JQ1, or lapatinib and JQ1 or (for SKBR-3) treated with siRNA pools (non-targeting control or FOXA1) prior to drug treatment before being used for ChIPseq (BRD4, MED1, H3K27Ac, or FOXA1 (for SKBR-3))

2020-11-03 | GSE160667 | GEO

BRG1-dependent regulation of Wnt signaling pathway during skeletal muscle differentiation

Project description:RNA-seq analysis for C2C12 myoblasts knocked down for either only-BRG1 or only-BRM or both BRG1 and BRM. Cells were treated with an siRNA SMARTpools of four oligos each targeting either BRG1 (siGENOME mouse Smarca4 pool #M-041135-01-0020) or BRM (siGENOME mouse Smarca2 pool #M-056591-00-0020) or both. Control samples were treated with non-targeting scrambled oligos (siRNA SMARTpool ON-TARGETplus scrambled non-targeting pool # D-001810-10-20). siRNA pools were purchased from Dharmacon, Horizon Discovery Ltd., USA.

2023-06-24 | GSE196283 | GEO

FOXA1-dependent responses of the HER2+ SKBR-3 cell line to lapatinib

Project description:FOXA1-dependent responses of the HER2+ SKBR-3 cell line to lapatinib

| PRJNA671641 | ENA

RNA-seq of human oesophageal adenocarcinoma OE19 cell line following PPARGC1A knock-down and 24 hour lapatinib treatment

Project description:To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with either DMSO or 500 nM lapatinib for 24 hours.

2022-09-26 | E-MTAB-10317 | biostudies-arrayexpress

Adaptive responses of the HER2+ SKBR-3 and BT474m1 cell lines to lapatinib and JQ1

Project description:Adaptive responses of the HER2+ SKBR-3 and BT474m1 cell lines to lapatinib and JQ1

| PRJNA671649 | ENA

Transcription profiling by array of human SKBR-3 cells VE-cadherin siRNA and then treated with retinoic acid

Project description:SKBR-3 cells were transfected with Luciferase siRNA or VE-cadherin siRNA and then treated with 10-7M retinoic acid (RA) for 48 hours.

2010-03-13 | E-MEXP-2418 | biostudies-arrayexpress

Human breast cancer SKBr-3 cells: trastuzumab-resistant vs. parental

2013-05-25 | GSE47011 | GEO

Targeting FAK and EGFR/HER-2 with small molecule inhibitors in SKBR-3 breast cancer cell

Project description:Targeting FAK with two different FAK inhibitors and Lapatinib demonstrated different signaling mechanisms

2015-09-25 | GSE61756 | GEO

Human breast cancer SKBr-3 cells: trastuzumab-resistant vs. parental

Project description:Human breast cancer SKBr-3 cells selected with trastuzumab for 6 month compared with parental SKBr-3 cells; Goal was to screen for microRNAs involved in development of trastuzumab resistance. Human breast cancer SKBr-3 cells were continuously cultured in the presence ofM-BM- 5M-BM-5g/ml trastuzumab for 6 months, and the resulting alive cells were regarded as trastuzumab-resistant. Total RNAs were prepared from these cells and cells cultured in parallel in control media, and were subjected to hybridization on the miRCURY LNA Array (Exiqon, version 11.0).

2013-05-25 | E-GEOD-47011 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data